TY - JOUR T1 - Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with HCV GT1 mono-infection and HIV/HCV coinfection (C-WORTHY): a randomised, open-label phase 2 trial JF - Lancet Y1 - 2015 A1 - M S Sulkowski A1 - Christophe Hézode A1 - Gerstoft, J. A1 - et, al ED - Vierling, J.M. ED - Mallolas, J. ED - Stanislas Pol ED - Kugelmas, M. ED - Murillo, A. ED - Weis, N. ED - Nahass, R. ED - Shibolet, O. ED - Serfaty, L. ED - Bourliere, M. ED - DeJesus, E. ED - E Zuckerman ED - Dutko, F. ED - Shaughnessy, M. ED - Hwang, P. ED - Howe, A.Y. ED - Wahl, J. ED - Robertson, M. ED - Barr, E. ED - Haber, B. VL - 285 SP - 1087-1097 IS - 9973 ER -